You are here

Humira

UCB posts more supportive data from Humira rival bimekizumab

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Flag link:

FDA approves latest Humira near-copy, as dozens of biosimilars head for market

FDA approves latest Humira near-copy, as dozens of biosimilars head for market

Pharmaforum

Flag link:

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Fierce Pharma

psoriatic arthritis

Flag link:

3 Most Important Takeaways From AbbVie's Q3 Results

3 Most Important Takeaways From AbbVie's Q3 Results

Motley Fool

Flag link:

Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

BioSpace

psoriatic arthritis

Flag link:

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

Fierce Pharma

Gilead Sciences

Flag link:

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Yahoo/Reuters

Flag link:

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Fierce Pharma

Bristol-Myers Squibb

Flag link:

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

Motley Fool

Flag link:

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

5 Things You Need to Know From AbbVie's Q2 Earnings Results

5 Things You Need to Know From AbbVie's Q2 Earnings Results

Motley Fool

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

Endpoints

Samsung Bioepis

Flag link:

Merck's biosimilar to AbbVie's Humira wins FDA approval

Merck's biosimilar to AbbVie's Humira wins FDA approval

Reuters

Flag link:

Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void

Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void

Fierce Pharma

Gilead Sciences

Flag link:

Why AbbVie's Stock Sank in the First Half of 2019

Why AbbVie's Stock Sank in the First Half of 2019

Motley Fool

Flag link:

5 reasons AbbVie bought Allergan, and why they may not be enough

5 reasons AbbVie bought Allergan, and why they may not be enough

Biopharma Dive

diversification

Flag link:

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

Stat

Flag link:

Meet the Top Ten Drugs of 2024 (Maybe)

Meet the Top Ten Drugs of 2024 (Maybe)

Drug Channels

Bristol-Myers Squibb

Flag link:

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Pharmaforum

psoriatic arthritis

Flag link:

Pages